Please enable JavaScript to continue using this application.

Compare $BBOT vs $FATE | Chartloom

Compare

$BBOT vs $FATE

BridgeBio Oncology Therapeutics Inc · Fate Therapeutics Inc

BBOT

BridgeBio Oncology Therapeutics Inc

FATE

Fate Therapeutics Inc

Compare $BBOT vs $FATE

Comparing BridgeBio Oncology Therapeutics Inc and Fate Therapeutics Inc

BBOTBridgeBio Oncology Therapeutics Inc

FATEFate Therapeutics Inc

BBOTBridgeBio Oncology Therapeutics Inc

Market cap

$265M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-73.1%

52W performance

-72.5%

FCF yield

-73.1%

FATEFate Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

54.34x

Rev growth (TTM)

-23.4%

YTD performance

120.2%

52W performance

44.4%

FCF yield

-41.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BBOT

FATE

Detailed metrics comparison

BBOT

BridgeBio Oncology Therapeutics Inc

FATE

Fate Therapeutics Inc

Market Cap

BBOT$265M

FATE$254M

Enterprise Value

BBOT$211M

FATE$234M

Price

BBOT$3.31

FATE$2.18

P/E Ratio

BBOTN/A

FATEN/A

P/S Ratio

BBOT0.00x

FATE39.15x

EV/Sales

BBOT0.00x

FATE35.98x

EV/EBITDA

BBOT0.00x

FATE0.00x

P/B Ratio

BBOT0.97x

FATE1.81x

P/FCF Ratio

BBOTN/A

FATEN/A

EV/FCF

BBOT-1.09x

FATE-2.21x

PEG Ratio

BBOTN/A

FATEN/A

Forward P/E (NTM)

BBOTN/A

FATEN/A

Forward P/S (NTM)

BBOTN/A

FATE54.34x

Revenue (TTM)

BBOT$0

FATE$6M

Revenue Growth (YoY)

BBOTN/A

FATE-23.4%

Forward Rev Growth

BBOT540.3%

FATE-17.6%

Gross Margin (TTM)

BBOT0.0%

FATE0.0%

Operating Margin (TTM)

BBOT0.0%

FATE0.0%

EBITDA Margin (TTM)

BBOT0.0%

FATE-1873.4%

Net Margin (TTM)

BBOT0.0%

FATE-1941.1%

FCF Margin (TTM)

BBOTN/A

FATE-1627.8%

Net Income (TTM)

BBOT$-182M

FATE$-126M

FCF (TTM)

BBOT$-194M

FATE$-106M

EPS (TTM)

BBOT-$2.27

FATE-$1.05

ROE (TTM)

BBOT-4690.0%

FATE-6508.0%

ROA (TTM)

BBOT-4217.0%

FATE-4173.0%

ROIC (TTM)

BBOT-4690.0%

FATE-6174.0%

Cash

BBOT$54M

FATE$32M

Debt

BBOT$0

FATE$12M

Net Cash/Debt

BBOT$54M

FATE$21M

Current Ratio (TTM)

BBOT4.69x

FATE4.85x

Quick Ratio (TTM)

BBOT4.38x

FATE4.74x

Debt/Equity (TTM)

BBOT0.00x

FATE0.08x

Debt/Assets (TTM)

BBOT0.0%

FATE0.0%

Interest Coverage (TTM)

BBOTN/A

FATEN/A

Net Debt/EBITDA (TTM)

BBOT0.00x

FATE0.00x

Beta

BBOT0.67

FATE2.67

52W Performance

BBOT-72.5%

FATE44.4%

YTD Performance

BBOT-73.1%

FATE120.2%

% from 52W High

BBOT-77.7%

FATE-32.5%

% from 52W Low

BBOT1.2%

FATE129.5%

Asset Turnover (TTM)

BBOT0.00x

FATE0.02x

FCF Yield (TTM)

BBOT-73.1%

FATE-41.6%

Earnings Yield (TTM)

BBOT-68.7%

FATE-49.6%

Dividend Yield (TTM)

BBOTN/A

FATEN/A

Rule of 40

BBOT0.0

FATE-1,651.1

EV/GP/RG

BBOTN/A

FATEN/A

Ticker research

View BBOT research View FATE research

Metric	BBOT BridgeBio Oncology Therapeutics Inc	FATE Fate Therapeutics Inc
Market & Valuation
Market Cap	$265M	$254M
Enterprise Value	$211M	$234M
Price	$3.31	$2.18
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	39.15x
EV/Sales	0.00x	35.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-2.21x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	54.34x
Revenue & Growth
Revenue (TTM)	$0	$6M
Revenue Growth (YoY)	N/A	-23.4%
Forward Rev Growth	540.3%	-17.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1873.4%
Net Margin (TTM)	0.0%	-1941.1%
FCF Margin (TTM)	N/A	-1627.8%
Net Income (TTM)	$-182M	$-126M
FCF (TTM)	$-194M	$-106M
EPS (TTM)	-$2.27	-$1.05
ROE (TTM)	-4690.0%	-6508.0%
ROA (TTM)	-4217.0%	-4173.0%
ROIC (TTM)	-4690.0%	-6174.0%
Financial Health
Cash	$54M	$32M
Debt	$0	$12M
Net Cash/Debt	$54M	$21M
Current Ratio (TTM)	4.69x	4.85x
Quick Ratio (TTM)	4.38x	4.74x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	2.67
52W Performance	-72.5%	44.4%
YTD Performance	-73.1%	120.2%
% from 52W High	-77.7%	-32.5%
% from 52W Low	1.2%	129.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-73.1%	-41.6%
Earnings Yield (TTM)	-68.7%	-49.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,651.1
EV/GP/RG	N/A	N/A
Ticker research	View BBOT research	View FATE research

Valuation

P/S Ratio

BBOT

0.00x

FATE

39.15x

EV/FCF

FATE

-2.21x

BBOT

-1.09x

Growth & revenue

Revenue Growth TTM

FATE

-23.4%

Forward Revenue Growth

BBOT

540.3%

FATE

-17.6%

Profitability & performance

Gross Margin

BBOT

0.0%

FATE

0.0%

ROE

BBOT

-4690.0%

FATE

-6508.0%

FCF Yield %

FATE

-41.6%

BBOT

-73.1%

52-Week Performance

FATE

44.4%

BBOT

-72.5%

Detailed metrics comparison

BBOT

BridgeBio Oncology Therapeutics Inc

FATE

Fate Therapeutics Inc

Market Cap

BBOT$265M

FATE$254M

Enterprise Value

BBOT$211M

FATE$234M

Price

BBOT$3.31

FATE$2.18

P/E Ratio

BBOTN/A

FATEN/A

P/S Ratio

BBOT0.00x

FATE39.15x

EV/Sales

BBOT0.00x

FATE35.98x

EV/EBITDA

BBOT0.00x

FATE0.00x

P/B Ratio

BBOT0.97x

FATE1.81x

P/FCF Ratio

BBOTN/A

FATEN/A

EV/FCF

BBOT-1.09x

FATE-2.21x

PEG Ratio

BBOTN/A

FATEN/A

Forward P/E (NTM)

BBOTN/A

FATEN/A

Forward P/S (NTM)

BBOTN/A

FATE54.34x

Revenue (TTM)

BBOT$0

FATE$6M

Revenue Growth (YoY)

BBOTN/A

FATE-23.4%

Forward Rev Growth

BBOT540.3%

FATE-17.6%

Gross Margin (TTM)

BBOT0.0%

FATE0.0%

Operating Margin (TTM)

BBOT0.0%

FATE0.0%

EBITDA Margin (TTM)

BBOT0.0%

FATE-1873.4%

Net Margin (TTM)

BBOT0.0%

FATE-1941.1%

FCF Margin (TTM)

BBOTN/A

FATE-1627.8%

Net Income (TTM)

BBOT$-182M

FATE$-126M

FCF (TTM)

BBOT$-194M

FATE$-106M

EPS (TTM)

BBOT-$2.27

FATE-$1.05

ROE (TTM)

BBOT-4690.0%

FATE-6508.0%

ROA (TTM)

BBOT-4217.0%

FATE-4173.0%

ROIC (TTM)

BBOT-4690.0%

FATE-6174.0%

Cash

BBOT$54M

FATE$32M

Debt

BBOT$0

FATE$12M

Net Cash/Debt

BBOT$54M

FATE$21M

Current Ratio (TTM)

BBOT4.69x

FATE4.85x

Quick Ratio (TTM)

BBOT4.38x

FATE4.74x

Debt/Equity (TTM)

BBOT0.00x

FATE0.08x

Debt/Assets (TTM)

BBOT0.0%

FATE0.0%

Interest Coverage (TTM)

BBOTN/A

FATEN/A

Net Debt/EBITDA (TTM)

BBOT0.00x

FATE0.00x

Beta

BBOT0.67

FATE2.67

52W Performance

BBOT-72.5%

FATE44.4%

YTD Performance

BBOT-73.1%

FATE120.2%

% from 52W High

BBOT-77.7%

FATE-32.5%

% from 52W Low

BBOT1.2%

FATE129.5%

Asset Turnover (TTM)

BBOT0.00x

FATE0.02x

FCF Yield (TTM)

BBOT-73.1%

FATE-41.6%

Earnings Yield (TTM)

BBOT-68.7%

FATE-49.6%

Dividend Yield (TTM)

BBOTN/A

FATEN/A

Rule of 40

BBOT0.0

FATE-1,651.1

EV/GP/RG

BBOTN/A

FATEN/A

Ticker research

View BBOT research View FATE research

Metric	BBOT BridgeBio Oncology Therapeutics Inc	FATE Fate Therapeutics Inc
Market & Valuation
Market Cap	$265M	$254M
Enterprise Value	$211M	$234M
Price	$3.31	$2.18
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	39.15x
EV/Sales	0.00x	35.98x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.81x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-2.21x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	54.34x
Revenue & Growth
Revenue (TTM)	$0	$6M
Revenue Growth (YoY)	N/A	-23.4%
Forward Rev Growth	540.3%	-17.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-1873.4%
Net Margin (TTM)	0.0%	-1941.1%
FCF Margin (TTM)	N/A	-1627.8%
Net Income (TTM)	$-182M	$-126M
FCF (TTM)	$-194M	$-106M
EPS (TTM)	-$2.27	-$1.05
ROE (TTM)	-4690.0%	-6508.0%
ROA (TTM)	-4217.0%	-4173.0%
ROIC (TTM)	-4690.0%	-6174.0%
Financial Health
Cash	$54M	$32M
Debt	$0	$12M
Net Cash/Debt	$54M	$21M
Current Ratio (TTM)	4.69x	4.85x
Quick Ratio (TTM)	4.38x	4.74x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	2.67
52W Performance	-72.5%	44.4%
YTD Performance	-73.1%	120.2%
% from 52W High	-77.7%	-32.5%
% from 52W Low	1.2%	129.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-73.1%	-41.6%
Earnings Yield (TTM)	-68.7%	-49.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-1,651.1
EV/GP/RG	N/A	N/A
Ticker research	View BBOT research	View FATE research